698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

Volume: 32, Pages: S710 - S711
Published: Sep 1, 2021
Abstract
Effective therapies are critically needed for previously treated patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC), particularly those considered hard-to-treat with poor prognostic factors. In the phase III EV-301 trial (NCT03474107), EV showed superior overall survival (OS) compared with standard chemotherapy (SC) in pts with previously treated la/mUC; this subgroup analysis evaluates the efficacy and safety of EV...
Paper Details
Title
698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Published Date
Sep 1, 2021
Volume
32
Pages
S710 - S711
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.